GLS
Glutaminase kidney isoform, mitochondrial
As of the edition of 20 October 2026, GLS (glutaminase kidney isoform, mitochondrial, UniProt O94925) has 2 drugs tested at it and 1 company on the list, 1 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- O94925
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Solved structures
- 50
- Disease areas
- Cancer; Pregnancy and women's health; Urinary and reproductive; Lungs and airways; Blood and lymph; Skin and connective tissue; Immune system; Digestive system
- Registered trials of its drugs
- 25
Drugs at this target
| Status | Count |
|---|---|
| Went quiet | 1 |
| Stopped | 1 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Telaglenastat | Stopped | Phase 2 | none listed |
| IPN-60090 | Went quiet | Phase 1 | none listed |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Total on the list | 1 |
| Company | Route |
|---|---|
| Calithera Biosciences | Route A |
The other 0 companies at GLS
In the product1 company in all; 0 are not named here, and no score is.
See the 1 companies at GLS, ranked, with the facts behind eachRequest access. Nothing is shown until you do.